{"assetProfile": {"address1": "5858 Horton Street", "address2": "Suite 170", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 318 9098", "website": "https://www.estrellabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Cheng  Liu Ph.D.", "age": 55, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jiandong  Xu", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400}, "calendarEvents": {"maxAge": 1, "earnings": {"earningsDate": [], "earningsCallDate": [], "earningsAverage": {}, "earningsLow": {}, "earningsHigh": {}, "revenueAverage": {}, "revenueLow": {}, "revenueHigh": {}}, "exDividendDate": {}, "dividendDate": {}}, "financialData": {"maxAge": 86400, "currentPrice": {"raw": 0.2357, "fmt": "0.24"}, "targetHighPrice": {}, "targetLowPrice": {}, "targetMeanPrice": {}, "targetMedianPrice": {}, "recommendationMean": {}, "recommendationKey": "none", "numberOfAnalystOpinions": {}, "totalCash": {"raw": 2479146, "fmt": "2.48M", "longFmt": "2,479,146"}, "totalCashPerShare": {"raw": 0.07, "fmt": "0.07"}, "ebitda": {}, "totalDebt": {"raw": 22000, "fmt": "22k", "longFmt": "22,000"}, "quickRatio": {"raw": 0.254, "fmt": "0.25"}, "currentRatio": {"raw": 0.282, "fmt": "0.28"}, "totalRevenue": {}, "debtToEquity": {}, "revenuePerShare": {}, "returnOnAssets": {"raw": -1.7475301, "fmt": "-174.75%"}, "returnOnEquity": {}, "grossProfits": {}, "freeCashflow": {"raw": 2812901, "fmt": "2.81M", "longFmt": "2,812,901"}, "operatingCashflow": {"raw": -1336121, "fmt": "-1.34M", "longFmt": "-1,336,121"}, "earningsGrowth": {}, "revenueGrowth": {}, "grossMargins": {"raw": 0.0, "fmt": "0.00%"}, "ebitdaMargins": {"raw": 0.0, "fmt": "0.00%"}, "operatingMargins": {"raw": 0.0, "fmt": "0.00%"}, "profitMargins": {"raw": 0.0, "fmt": "0.00%"}, "financialCurrency": "USD"}}